Comparative effectiveness questions in oncology

New England Journal of Medicine

Volumn 370, Issue 16, 2014, Pages 1478-1481

  Mailankody, Sham ^a   Prasad, Vinay ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; KETOCONAZOLE; PACLITAXEL;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; HUMAN; ONCOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SHORT SURVEY;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; COMPARATIVE EFFECTIVENESS RESEARCH; DRUG COSTS; HUMANS; KETOCONAZOLE; MEDICAL ONCOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84898651926     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1400104     Document Type: Article

References (5)

1. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439-42.
2. Hall SS. The cost of living. New York Magazine. October 20, 2013 (http://nymag.com/news/features/cancer-drugs-2013-10).
3. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33. (Pubitemid 41095034)
4. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
5. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.